Centogene BV: Tumbles on weak quarterly revenue
** U.S.-listed shares of Germany based diagnostic and pharma
co CNTG.O fall 10% to $9.9
** Posts Q2 revenue of 9.7 mln euros, a 13.3% drop from a
year-ago urn:newsml:reuters.com:*:nGNX6kDPS1
** Co says decrease in sample volume related to routine
diagnostics business and pharmaceutical collaborations led to
lower rev
** Sees FY 2020 rev between 60 mln euros to 65 mln euros
** Stock down ~1% YTD
(Reporting by Shivani Kumaresan in Bengaluru)
((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780;))
Recent news on Crown LiquidationCo NV in liquidatie
See all newsBrief: Centogene Signs Strategic Transaction With Private Equity Group Charme Capital Partners
Brief: Centogene Announces Adoption Of All Resolutions Tabled At 2024 Annual General Meeting
Brief: Centogene NV Says Agreements With LIFERA Provides Funding In Aggregate Of About $20 Mln To Co
Brief: Centogene And Evotec Discover Promising New Molecule To Treat Gaucher Disease
Brief: Centogene Receives Nasdaq Non-Compliance Notice